Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Brainsway Ltd. Sponsored ADR BWAY

Healthcare  —  Medical Devices
13.31 0.10 0.76% as of 25 Sep
Market cap
$531.6M
P/E
28.9×
Cash Flow Champion (3y) Revenue Champion (3y)
Growth Flags show if company had growth for consecutive years
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Brainsway Ltd. Sponsored ADR (BWAY) Business Profile

Updated before January 2025

Company Overview

Brainsway Ltd. Sponsored ADR (BWAY) is a global leader in advanced non-invasive neurostimulation treatments for mental health disorders. Founded in 2003 and headquartered in Jerusalem, Israel, Brainsway has revolutionized the field of mental health care with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology. The company was co-founded by Dr. Abraham Zangen and Dr. Yiftach Roth, who are pioneers in the field of brain stimulation. Brainsway’s leadership team includes experienced professionals in neuroscience, medical technology, and business management, with Christopher von Jako serving as the CEO. The company is publicly traded on the NASDAQ under the ticker symbol BWAY.

Core Business Segments

Brainsway operates primarily in the mental health and neurostimulation sectors, offering innovative solutions for the treatment of various mental health conditions. The company’s core business segments include:

1. Deep TMS Systems

Brainsway’s flagship product is its Deep TMS system, which is FDA-cleared and CE-marked for the treatment of several mental health disorders, including:

  • Major Depressive Disorder (MDD): A non-invasive treatment option for patients who have not responded to traditional therapies.
  • Obsessive-Compulsive Disorder (OCD): The first and only FDA-cleared TMS device for OCD treatment.
  • Smoking Cessation: Recently approved for aiding individuals in quitting smoking.

2. Treatment Protocols and Accessories

Brainsway provides specialized treatment protocols tailored to specific conditions. These protocols are supported by a range of accessories, including coils and head caps, designed to enhance the efficacy and comfort of the treatment process.

3. Service and Support

The company offers comprehensive service and support packages to healthcare providers, ensuring seamless integration of Deep TMS systems into clinical practices. This includes training, technical support, and ongoing maintenance.

Business Model

Brainsway operates on a hybrid business model that combines product sales with recurring revenue streams. The company generates revenue through:

  • Device Sales: Selling Deep TMS systems to hospitals, clinics, and mental health centers.
  • Leasing Agreements: Offering flexible leasing options to make the technology accessible to a broader range of healthcare providers.
  • Consumables and Accessories: Generating recurring revenue from the sale of disposable caps and other accessories required for treatment sessions.
  • Service Contracts: Providing ongoing support and maintenance services to ensure optimal device performance.

This diversified revenue model allows Brainsway to maintain financial stability while expanding its market reach.

Strategic Direction

Brainsway is committed to advancing mental health care through innovation and global expansion. The company’s strategic priorities include:

  • Expanding Indications: Conducting clinical trials to secure regulatory approvals for additional indications, such as post-traumatic stress disorder (PTSD) and Alzheimer’s disease.
  • Geographic Expansion: Increasing its presence in key markets, including North America, Europe, and Asia-Pacific.
  • Technological Innovation: Investing in research and development to enhance the efficacy and usability of its Deep TMS systems.
  • Sustainability Goals: Implementing environmentally friendly practices in manufacturing and operations to reduce its carbon footprint.

Competitive Landscape

Brainsway operates in a competitive market, facing challenges from both established players and emerging startups. Key competitors include:

  • Neuronetics, Inc.: A leading provider of TMS therapy for depression.
  • Magstim: Known for its range of TMS devices and accessories.
  • Flow Neuroscience: A startup offering wearable brain stimulation devices for at-home use.
  • Alto Neuroscience: Focused on AI-driven mental health solutions.

Despite the competition, Brainsway differentiates itself through its proprietary Deep TMS technology, which offers deeper and broader brain stimulation compared to traditional TMS systems.

Risk Factors

Brainsway faces several risks that could impact its business operations and financial performance:

  • Regulatory Challenges: Delays in obtaining regulatory approvals for new indications could hinder growth.
  • Market Dependence: Reliance on a limited number of products and indications makes the company vulnerable to market fluctuations.
  • Supply Chain Disruptions: Dependence on third-party suppliers for components could lead to production delays.
  • Competition: Intense competition in the neurostimulation market could pressure pricing and margins.
  • Economic Conditions: Economic downturns could reduce healthcare spending, affecting demand for Brainsway’s products.

Recent Developments

Brainsway has made significant strides in recent years, including:

  • FDA Approval for Smoking Cessation: In 2021, the company received FDA clearance for its Deep TMS system as a treatment for smoking cessation, opening a new revenue stream.
  • Partnerships: Collaborating with leading healthcare providers to expand access to Deep TMS treatments.
  • Technological Advancements: Launching next-generation Deep TMS systems with improved user interfaces and treatment capabilities.
  • Global Expansion: Establishing new distribution agreements in Asia and South America to tap into emerging markets.

Investment Considerations

Investors considering Brainsway should weigh the following factors:

Strengths

  • Innovative Technology: Proprietary Deep TMS technology with multiple FDA clearances.
  • Growing Market: Increasing demand for non-invasive mental health treatments.
  • Recurring Revenue: Diversified revenue streams from device sales, leasing, and consumables.
  • Global Presence: Expanding footprint in key international markets.

Risks

  • Regulatory Dependence: Success hinges on obtaining and maintaining regulatory approvals.
  • Market Competition: Facing competition from established players and new entrants.
  • Economic Sensitivity: Vulnerable to changes in healthcare budgets and economic conditions.

Conclusion

Brainsway Ltd. is a trailblazer in the field of non-invasive neurostimulation, offering innovative solutions for mental health care. With its proprietary Deep TMS technology, the company is well-positioned to capitalize on the growing demand for effective mental health treatments. While challenges such as regulatory hurdles and market competition persist, Brainsway’s commitment to innovation and global expansion provides a strong foundation for future growth. As mental health continues to gain prominence as a global health priority, Brainsway is poised to play a pivotal role in shaping the future of mental health care.